Aristea: Aristea Therapeutics Announces Dosing of First Patient in Open-Label Extension for Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis
SAN DIEGO, June 30, 2022 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing no...
Read full article »
Aristea is a California-based biotechnology firm that develops and commercializes novel therapies for the treatment of inflammatory diseases.
Read more